BM and PB analyses showed that independently of ELN risk categories [2], the majority of MΦs in AML patients expressed CD163 (Figure 1A), a marker frequently associated with a protumoral phenotype [18,19,20,21]. This evidence concerns the gene CD163 and acute myeloid leukemia.